Jazz Pharmaceuticals
JAZZ
649 hedge funds and large institutions have $15.5B invested in Jazz Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 132 funds opening new positions, 243 increasing their positions, 190 reducing their positions, and 56 closing their positions.
136% more first-time investments, than exits
New positions opened: 132 | Existing positions closed: 56
28% more repeat investments, than reductions
Existing positions increased: 243 | Existing positions reduced: 190
12% more funds holding
Funds holding: 578 → 649 (+71)
0% more funds holding in top 10
Funds holding in top 10: 13 → 13 (0)
3% less capital inflows, than outflows
Capital inflows: $1.96B | Capital outflows: $2.03B
7% less call options, than puts
Call options by funds: $47.1M | Put options by funds: $50.7M
3.21% less ownership
Funds ownership: 105.67% → 102.46% (-3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$511M |
| 2 |
Mariner
Overland Park,
Kansas
|
+$125M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$94.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$87.6M |
| 5 |
Two Sigma Investments
New York
|
+$83.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$323M |
| 2 |
Holocene Advisors
New York
|
-$126M |
| 3 |
Millennium Management
New York
|
-$109M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$86.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$78.6M |
JAZZ Hedge Fund Activity: Q2 2026 in Review
649 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q2 2026, worth a combined $15.5B — up 26% from $12.3B a quarter earlier.
Buyers outnumbered sellers: 132 funds opened new JAZZ positions and 56 closed out — a net gain of 76 holders — while 243 added to existing stakes and 190 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $511M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $323M sold.
- 649 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q2 2026, up from 578 in Q1 2026.
- Funds reported $15.5B of Jazz Pharmaceuticals stock for Q2 2026, up 26% quarter-over-quarter.
- 132 funds opened new Jazz Pharmaceuticals positions in Q2 2026 and 56 closed out, a net change of +76 holders.
- The largest Jazz Pharmaceuticals buyer in Q2 2026 was Fidelity Investments, an estimated $511M added.
- The largest Jazz Pharmaceuticals seller in Q2 2026 was EcoR1 Capital, an estimated $323M sold.
Based on aggregated 13F filings for Q2 2026.